Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed Products


Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC today announced that they have entered into a License Agreement to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada. The pseudoephedrine-containing NEXAFED brand products utilize Acura's IMPEDEA Technology which disrupts the extraction and conversion of the pseudoephedrine into the illicit drug, methamphetamine.



from Biotech News